FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
DualityBio Inc.
Fate Therapeutics
Hoffmann-La Roche
NKGen Biotech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)